Researcher profile

Halil Kilicoglu

Halil Kilicoglu contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 15 - UnverifiedVerification L1Unclaimed author
3works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2026arXiv

Robust Biomedical Publication Type and Study Design Classification with Knowledge-Guided Perturbations

Accurately and consistently indexing biomedical literature by publication type and study design is essential for supporting evidence synthesis and knowledge discovery. Prior work on automated publication type and study design indexing has primarily focused on expanding label coverage, enriching feature representations, and improving in-domain accuracy, with evaluation typically conducted on data drawn from the same distribution as training. Although pretrained biomedical language models achieve strong performance under these settings, models optimized for in-domain accuracy may rely on superficial lexical or dataset-specific cues, resulting in reduced robustness under distributional shift. In this study, we introduce an evaluation framework based on controlled semantic perturbations to assess the robustness of a publication type classifier and investigate robustness-oriented training strategies that combine entity masking and domain-adversarial training to mitigate reliance on spurious topical correlations. Our results show that the commonly observed trade-off between robustness and in-domain accuracy can be mitigated when robustness objectives are designed to selectively suppress non-task-defining features while preserving salient methodological signals. We find that these improvements arise from two complementary mechanisms: (1) increased reliance on explicit methodological cues when such cues are present in the input, and (2) reduced reliance on spurious domain-specific topical features. These findings highlight the importance of feature-level robustness analysis for publication type and study design classification and suggest that refining masking and adversarial objectives to more selectively suppress topical information may further improve robustness. Data, code, and models are available at: https://github.com/ScienceNLP-Lab/MultiTagger-v2/tree/main/ICHI

preprint2026arXiv

When Evidence Conflicts: Uncertainty and Order Effects in Retrieval-Augmented Biomedical Question Answering

Biomedical retrieval-augmented large language models (LLMs) often face evidence that is incomplete, misleading, or internally contradictory, yet evaluation usually emphasizes answer accuracy under helpful context rather than reliability under conflict. Using HealthContradict, we evaluate six open-weight LLMs under five controlled evidence conditions: no retrieved context, correct-only context, incorrect-only context, and two mixed conditions containing both correct and contradictory documents in opposite orders. In this conflicting-evidence order contrast, where the same two documents are both present and only their order is reversed, accuracy drops for every model and 11.4%--25.2% of predictions flip. To support abstention in these difficult cases, we also evaluate a conflict-aware abstention score that combines model confidence with a detector of evidence conflict. In the two hardest conditions, this score improves selective accuracy over confidence-only, with mean gains of 7.2--33.4 points in incorrect-only (`IC') and 3.6--14.4 points in incorrect-first conflicting (`ICC') conditions across 75%, 50%, and 25% coverage. These results show that conflicting biomedical evidence is both an uncertainty and robustness problem and motivate evaluation and abstention methods that explicitly account for evidence disagreement.

preprint2021arXiv

Drug Repurposing for COVID-19 via Knowledge Graph Completion

Objective: To discover candidate drugs to repurpose for COVID-19 using literature-derived knowledge and knowledge graph completion methods. Methods: We propose a novel, integrative, and neural network-based literature-based discovery (LBD) approach to identify drug candidates from both PubMed and COVID-19-focused research literature. Our approach relies on semantic triples extracted using SemRep (via SemMedDB). We identified an informative subset of semantic triples using filtering rules and an accuracy classifier developed on a BERT variant, and used this subset to construct a knowledge graph. Five SOTA, neural knowledge graph completion algorithms were used to predict drug repurposing candidates. The models were trained and assessed using a time slicing approach and the predicted drugs were compared with a list of drugs reported in the literature and evaluated in clinical trials. These models were complemented by a discovery pattern-based approach. Results: Accuracy classifier based on PubMedBERT achieved the best performance (F1= 0.854) in classifying semantic predications. Among five knowledge graph completion models, TransE outperformed others (MR = 0.923, Hits@1=0.417). Some known drugs linked to COVID-19 in the literature were identified, as well as some candidate drugs that have not yet been studied. Discovery patterns enabled generation of plausible hypotheses regarding the relationships between the candidate drugs and COVID-19. Among them, five highly ranked and novel drugs (paclitaxel, SB 203580, alpha 2-antiplasmin, pyrrolidine dithiocarbamate, and butylated hydroxytoluene) with their mechanistic explanations were further discussed. Conclusion: We show that an LBD approach can be feasible for discovering drug candidates for COVID-19, and for generating mechanistic explanations. Our approach can be generalized to other diseases as well as to other clinical questions.